Challenging Scenario in the Treatment Paradigm for Patient with Pulmonary Tuberculosis in Systemic Sclerosis Associated Interstitial Lung Disease – Case Series
Authors/Creators
- 1. Junior Resident (PG), Department of Pulmonology, Kakatiya Medical College and Govt CD & TB hospital Hanmakonda, Telangana
- 2. Associate Professor, Department of Pulmonology, Kakatiya Medical College and Govt CD & TB hospital Hanmakonda, Telangana
- 3. Assistant Professor, Department of Pulmonology, Kakatiya Medical College and Govt CD & TB hospital Hanmakonda, Telangana
- 4. Professor and HOD, Department of Pulmonology, Kakatiya Medical College and Govt CD & TB hospital Hanmakonda, Telangana
Description
Systemic sclerosis (SSc) is a connective tissue disease marked by immune irregularities, vasculopathy, and excessive collagen production, leading to fibrosis of the skin and internal organs. While SSc can affect multiple organs and systems, lung involvement, particularly interstitial lung disease (ILD), is the primary cause of mortality in this condition. We present here an interesting case of a patient with pulmonary tuberculosis with systemic sclerosis-associated interstitial lung disease.
Abstract (English)
Systemic sclerosis (SSc) is a connective tissue disease marked by immune irregularities, vasculopathy, and excessive collagen production, leading to fibrosis of the skin and internal organs. While SSc can affect multiple organs and systems, lung involvement, particularly interstitial lung disease (ILD), is the primary cause of mortality in this condition. We present here an interesting case of a patient with pulmonary tuberculosis with systemic sclerosis-associated interstitial lung disease.
Files
IJPCR,Vol16,Issue6,Article24.pdf
Files
(3.3 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:f0dba527f572d5aa576a3efe2c10d4f9
|
3.3 MB | Preview Download |
Additional details
Dates
- Accepted
-
2024-06-07
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue6,Article24.pdf
- Development Status
- Active
References
- 1. Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: A Comprehensive Review. Clin Rev Allergy Immunol. 2017 Dec;53(3):306- 336. 2. Del Rio AP, Sachetto Z, Sampaio-Barros PD, Marques-Neto JF, Londe AC, Bertolo MB. HLA markers for poor prognosis in systemic sclerosis Brazilian patients. Dis Markers. 2013 ;35(2):73-8. 3. Lambert NC, Distler O, Müller-Ladner U, Tylee TS, Furst DE, Nelson JL. HLADQA1*0501 is associated with diffuse systemic sclerosis in Caucasian men. Arthritis Rheum. 2000; 43:2005–10. 4. Radstake TRDJ, Gorlova O, Rueda B, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nature Genetics. 2010; 42:426– 29. 5. Zhou X, Lee JE, Arnett FC, et al. HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans. Arthritis and Rheumatism. 2009;60(12):3807–14. 6. Truchetet ME, Brembilla NC, Chizzolini C. Current Concepts on the Pathogenesis of Systemic Sclerosis. Clin Rev Allergy Immunol. 2023 Jun;64(3):262-283. 7. Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020 Mar; 8 (3):304-320. 8. Adigun R, Goyal A, Hariz A. Systemic Sclerosis (Scleroderma) [Updated 2024 Apr 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/N BK430875/ [Assessed on Feb 20th 2024] 9. Hassoun PM. Lung involvement in systemic sclerosis. Presse Med. 2011;40(1 Pt 2):e3-e17. 10. Ranu H, Wilde M, Madden B. Pulmonary function tests. Ulster Med J. 2011 May;80(2): 84-90. 11. Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res. 2019 Jan 18;20(1):13. 12. Nihtyanova SI, Denton CP. Pathogenesis of systemic sclerosis-associated interstitial lung disease. J Scleroderma Relat Disord. 2020 Mar; 5(2 Suppl):6-16.